Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma

• Päätekijät: Shun Zhang (Tekijä), Yixin Wang (Tekijä), Yifan Cao (Tekijä), Jin Wu (Tekijä), Zubin Zhang (Tekijä), Haigang Ren (Tekijä), Xiaohui Xu (Tekijä), Elena Kaznacheyeva (Tekijä), Qing Li (Tekijä), Guanghui Wang (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Frontiers Media S.A., 2022-03-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Hepatocellular carcinoma (HCC) is one of the most common fatal malignancies and the main cause of cancer-related deaths. The multitarget tyrosine kinase inhibitors (TKIs) sorafenib and regorafenib are systemic therapeutic drugs approved for the treatment of HCC. Here, we found that sorafenib and reg...